AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Thoracoabdominal Artery Stent Graft System Exploratory Study

RecruitingNAAges 18 Years - 80 YearsAllLifetech Scientific (Shenzhen) Co., Ltd.
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

This study is designed as a single-center, prospective, single-arm, open-label, exploratory study. The objective is to evaluate the feasibility of Thoracoabdominal Artery Stent Graft System for endovascular treatment of Thoracoabdominal aortic aneurysms (TAAA).

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: 1. Age: 18 to 80 years old; 2. Patients diagnosed with a Thoracoabdominal aortic aneurysm (based on the modified Crawford classification and European Society for Vascular Surgery (ESVS) 2019 Clinical Practice Guidelines on the Management of Abdominal Aorto-iliac Artery Aneurysms), and should meet at least ONE of the following conditions: 1. Maximum diameter of TAAA is \>50 mm; 2. TAAA diameter increases by more than 5 mm in the past 6 months or by more than 10 mm in the past 1 year; 3. Definite symptoms associated with TAAA, such as abdominal pain and back pain. 3. Anatomical Criteria 1. Proximal landing zone (aorta or implanted graft): the diameter ranges from 17 to 36 mm, and length should be โ‰ฅ25 mm; 2. Distal landing zone (aorta or implanted graft): If distal landing zone is in iliac artery, distal landing zone diameter ranges from 7 to 25 mm, and length should be โ‰ฅ15 mm; If the distal landing zone is in the abdominal aorta, distal landing zone diameter ranges from 12 to 36 mm, and length should be โ‰ฅ20 mm. 3. Visceral branch landing zone: the diameter ranges from 6 to 13 mm, and the length should be โ‰ฅ15 mm; 4. Renal artery landing zone: the diameter ranges from 4.5 to 9 mm, and the length should be โ‰ฅ15 mm; 5. Appropriate iliac, femoral, and upper limb arterial access. 4. Patients who understand the purpose of the study, volunteer to participate and sign the informed consent form, and are willing to complete follow-up as required by the protocol; 5. Patients do not want to or cannot wait for the approved alternative Exclusion Criteria: Exclusion Criteria (not eligible if any of the criteria is met): 1. Patients with ruptured thoracoabdominal aortic aneurysms in unstable hemodynamic condition; 2. Patients with thoracoabdominal aortic dissection; 3. Patients with infected or mycotic thoracoabdominal aortic aneurysms; 4. Patients with systemic or local infections that may increase the risk of endovascular graft infection; 5. Patients with occluded superior mesenteric artery, celiac trunk artery, or renal artery; 6. Patients requiring simultaneous coverage or embolization of bilateral internal iliac arteries; 7. Patients with severe stenosis, calcification or mural thrombus at stent-graft landing zone, and this situation leads to difficulty in adhering the covered stent or affecting the patency of the stent; 8. Patients with a history of acute coronary syndrome within the recent 6 months; Acute coronary syndrome refers to acute cardiac ischemic syndrome caused by rupture or erosion of unstable atherosclerotic plaques in the coronary artery and fresh thrombosis, including ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI) and unstable angina pectoris. 9. Patients with transient ischemic attack (TIA) or ischemic/hemorrhagic stroke within the recent 3 months; 10. Patients with abnormal liver and kidney function before operation \[alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> 5 times the upper limit of normal value; Serum creatinine (Cr) \>150umol/L\]; 11. Patients with severe pulmonary insufficiency who cannot tolerate general anesthesia;
๐Ÿ’Š

What it tests

  • The system includes the G-Branchโ„ข thoracoabdominal aortic stent graft system, the peripheral vascular stent graft system, and the aortic extension stent graft system
๐Ÿ“

Where

1 site
Asklepios Klinik Nord Heidberg
Hamburg, Germany
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy